Board Member
BridgeBio Pharma, Inc. (BBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsNeil Kumar is recorded as CEO and Board Member at BridgeBio Pharma, Inc. (BBIO). The newest filing on record that lists Neil Kumar as CEO and Board Member at BridgeBio Pharma, Inc. (BBIO) is dated April 24, 2026. The proxy statement of BridgeBio Pharma, Inc. reports total compensation of $14,944,585 for Neil Kumar in fiscal 2025, including a base salary of $1,044,000. Disclosed compensation is on record for 8 fiscal years. Neil Kumar has spoken on 7 earnings calls and 2 other investor events across 1 company, most recently for BridgeBio Pharma, Inc. on October 29, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO), Thomas Trimarchi (CFO and COO) and 7 others.
“Thanks, Chinmay, and thanks, everyone, for joining Today, as always, these calls are where we communicate relevant aspects of our business to investors, and so we welcome your questions and feedback.”
“As always, these calls are where we communicate relevant aspects of our business to investors and so we welcome your questions and feedback in sessions past we've had occasion to marry comments on the portfolio with comments regarding financing and strategy today however i want to focus entirely on the portfolio…”
“As always, this is a forum in which we communicate salient aspects of our business that are of interest to investors, and we welcome your questions and feedback along the way.”
“Obviously, we've noted the pullback and the disconnect between intrinsic value and where the stock's trading now. I'd say, first, we feel very privileged to be sitting on top of the last three phase threes, certainly in ADH1, LGMD2I, and the latest in Acon Traplasia.”
“Obviously, we've noted the pullback and the disconnect between intrinsic value and where the stock's trading now. I'd say first, we feel very privileged to be sitting on top of the last three phase threes, certainly in ADH1, LGMD2I, and the latest in ACA contraplasia.”
Start not stated–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $1,044,000 | $14,944,585 |
| 2024 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $987,539 | $15,581,923 |
| 2023 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $742,000 | $12,158,626 |
| 2022 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $1,106,000 | $6,674,437 |
| 2021 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $725,000 | $25,626,959 |
| 2020 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $550,000 | $10,054,909 |
| 2019 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $502,765 | $26,334,063 |
| 2018 | BridgeBio Pharma, Inc. (BBIO) | Chief Executive Officer | $450,000 | $450,000 |
